You are here: Industry Insights > COVID-19

News List

Calquence fails to prevent respiratory failure in COVID-19 patients europeanpharmaceuticalreview
November 16, 2020
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
Flamma Continues Veklury Partnership with Gilead for Covid-19 americanpharmaceuticalreview
November 16, 2020
Flamma entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury? (remdesivir) supply chain.
Study recommends steroid treatment should be given only to sickest COVID-19 patients expresspharma
November 16, 2020
While dexamethasone and other steroids are prescribed to treat cytokine storms, these drugs can backfire in patients whose immune response is already suppressed.
Swissmedic Begins Rolling Review of Moderna’s mRNA COVID-19 Vax contractpharma
November 16, 2020
Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22.
JAMA Reports Fluvoxamine as Potential Early Treatment for COVID-19 prnewswire
November 13, 2020
The COVID-19 Early Treatment Fund (CETF), announced that JAMA, The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that ...
Lack of skill and talent biggest challenge to digital transformation in pharma europeanpharmaceuticalreview
November 13, 2020
A report has found that the biggest hurdle for digital transformation in pharma is a lack of specific skills and talents, followed by organisational silos.
FDA grants emergency use authorisation to COVID-19 antibody bamlanivimab europeanpharmaceuticalreview
November 13, 2020
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency use in recently diagnosed patients who are at risk of developing severe COVID-19.
Stem cell therapy trial for COVID-19 patients with ARDS advised to continue europeanpharmaceuticalreview
November 13, 2020
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
Zydus concludes Phase II trials of Pegylated Interferon alpha-2b for COVID-19, to begin Phase III trials expresspharma
November 13, 2020
In 19 out of 20 patients, a single 1 mcg/kg dose of the drug demonstrated viral clearance as assessed by RT-PCR and a significant improvement in clinical symptoms, informs the company.
Gates Foundation offers $70 mn additional funding for COVID-19 vaccines expresspharma
November 13, 2020
$50 million will go to the COVAX Advance Market Commitment (AMC) and $20 million to the Coalition for Epidemic Preparedness Innovations (CEPI).